This Biotech Had Good News for Hair Loss Sufferers. So Why Is the Stock Sinking?
Nektar Therapeutics reports sustained hair regrowth after treatment ended, while analysts see positive implications for a competing drug. Continue Reading
YENOM NOTICIAS
Qué está moviendo el mercado.
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
These 2 ‘Monster Growth’ Stocks Aren’t Done Climbing, Say Analysts
Ask any old-school market investor and he'll tell you that the cliché is true, and 'past performance cannot guarantee future returns.' If that were true without exception, then growth investing would not be a viable option – but we all kno…
Biotech Breakout: What's in focus after Moderna's cancer win?
[mRNA or messenger RNA. The concept of mRNA vaccine. Innovative methods to treat virus. 3d render] Krot Studio INVESTORS SHOULD KNOW: A major Phase 3 trial win from Moderna (MRNA [https://seekingalpha.com/symbol/MRNA]) and Merck (MRK [http…
Q32 Bio prices $200M equity raise
* Q32 Bio (QTTB [https://seekingalpha.com/symbol/QTTB]) priced [https://seekingalpha.com/pr/20583043-q32-bio-announces-pricing-of-200-million-public-offering-of-common-stock-and-pre-funded] an underwritten public offering expected to raise…
Top Biotech Gainers: QTTB Sends Strong SIGNAL; AMWL And SI In Focus
(RTTNews) - Today's top biotech gainers include Q32 Bio, following positive Phase 2 results for its hair loss treatment; Agenus, as it advances development of its colon cancer drug combination, botensilimab and balstilimab; and Shoulder In…
Why Q32 Bio Stock Skyrocketed Today
Key Points Q32 Bio is striving to develop a safe and effective therapy for alopecia areata. Wall Street is excited about the data from a recent clinical study.10 stocks we like better than Q32 Bio › Shares of Q32 Bio (NASDAQ: QTTB) soared…
Q32 Bio announces $200M offering of common stock and pre-funded warrants
Q32 Bio (QTTB [https://seekingalpha.com/symbol/QTTB]) announced on Monday that it has commenced an underwritten public offering of $200M of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants t…
Q32 Bio Reports Positive 36-Week SIGNAL-AA Results In Alopecia Areata; Stock Up In Pre-market
(RTTNews) - Q32 Bio Inc. (QTTB), a clinical-stage biotechnology company announced positive 36-week topline results from Part B of the SIGNAL-AA Phase 2a trial evaluating Bempikibart in patients with severe or very severe alopecia areata (A…
Health Care had the best week vs. the S&P 500 on record
[Health Care Medical Stock Market Industry Sector Wall Street Buildings 3d Illustration] iQoncept/iStock via Getty Images The health care sector (XLV [https://seekingalpha.com/symbol/XLV]) had its best week against the S&P 500 (SP500 [http…
Quant rating check: Top oncology peers as Nuvalent goes private in $10.6B deal with GSK
The targeted oncology sector is shifting after GSK (GSK [https://seekingalpha.com/symbol/GSK]) decided to buy [https://seekingalpha.com/news/4601644-gsk-to-buy-nuvalent-for-106b] Nuvalent (NUVL [https://seekingalpha.com/symbol/NUVL]) for $…
Top Biotech Gainers: QTTB Has A Good Hair Day, GH Wins ACS Recommendation, Ebola Lifts SNGX, NNVX
(RTTNews) - Today's Top Gainers list features Q32 Bio, which announced a $55 million private placement financing; Soligenix, which is exploring the suitability of its ThermoVax platform to fight the Bundibugyo strain of Ebola virus; P3 Hea…
Q32 Bio Secures $55 Million Private Placement to Advance Alopecia Areata Pipeline (QTTB)
medical research microscope hands NEW SIZE ©National Institutes of Health Q32 Bio raised approximately $55 million in a private placement led by major healthcare investors as the company continues development of its Phase 2 alopecia areata…
Best Momentum Stocks to Buy for March 27th
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, March 27: Magnolia Oil & Gas Corporation MGY: This oil and natural gas company has a Zacks Rank #1 and witnessed the Zacks Consensus E…
New Strong Buy Stocks for March 27th
Here are five stocks added to the Zacks Rank #1 (Strong Buy) List today: Denison Mines Corp. DNN: This uranium exploration and mining company has seen the Zacks Consensus Estimate for its current year earnings increasing 16.7% over the las…
Best Momentum Stocks to Buy for March 19th
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, March 19: FIGS, Inc. FIGS: This healthcare apparel company has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its curr…
New Strong Buy Stocks for March 19th
Here are five stocks added to the Zacks Rank #1 (Strong Buy) List today: FIGS, Inc. FIGS: This healthcare apparel company has seen the Zacks Consensus Estimate for its current year earnings increasing 90% over the last 60 days. FIGS, Inc.…
New Strong Buy Stocks for March 13th
Here are five stocks added to the Zacks Rank #1 (Strong Buy) List today: Taboola.com Ltd. TBLA: This company which operates as an artificial intelligence-based algorithmic engine platform has seen the Zacks Consensus Estimate for its curre…
Alopecia Areata Market Set to Expand by 2036, Due to the Emergence of Novel Drug Classes Such as OX40L Inhibitors, IL-2 Inhibitors, IL-7Rα, and Others | DelveInsight
The alopecia areata market is expected to grow significantly as awareness of the condition increases, potentially expanding further in the coming years, supported by rising prevalence. Additionally, the launch of emerging therapies such as…
Akebia Therapeutics Expands Portfolio Beyond Anemia with New Rare Kidney Disease Pipeline Centered on AKB-097 and Praliciguat
Akebia Therapeutics Inc. (NASDAQ:AKBA) is one of the cheap penny stocks to invest in. On December 1, Akebia Therapeutics announced the official establishment of its rare kidney disease pipeline. This expansion is centered on two primary pr…
This Penny Biotech Stock Just Doubled on a Key Acquisition. Should You Buy Shares Here?
Q32 Bio (QTTB) shares more than doubled on Dec. 1 after the biotechnology company announced a strategic deal with the Cambridge-headquartered Akebia Therapeutics (AKBA). Q32 sold its Phase complement inhibitor, ADX-097, to Akebia for $12 m…
Q32 Bio Sells Complement Inhibitor ADX-097 To Akebia Therapeutics
(RTTNews) - Q32 Bio Inc. (QTTB) has sold its Phase 2 complement inhibitor ADX-097 to Akebia Therapeutics, Inc. (AKBA), securing upfront and milestone payments that will extend its cash runway into the second half of 2027. ADX-097, a humani…
Top Midday Gainers
Q32 Bio's (QTTB) shares doubled amid heavy trading after the company said Monday it sold alopecia ar PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
BC-Most Active Stocks
NEW YORK (AP) — prices for the Nasdaq composite, NYSE and NYSE American listed most active stocks. Nasdaq most active stocks: Stock Name Volume High Low Last Change Direct Digital Holdings Inc. 237,043,770 0.1799 0.1469 0.1501 +0.0349 Q32…
Akebia Announces Establishment of Rare Kidney Disease Pipeline
Acquires next generation tissue-targeted C3d-Factor H fusion protein complement inhibitor from Q32 Bio Phase 2 basket trial planned to evaluate complement inhibitor in multiple rare kidney disease indications Phase 2 trial of Praliciguat,…
Q32 Bio GAAP EPS of -$0.60 beats by $0.59
* Q32 Bio press release [https://seekingalpha.com/pr/20305704-q32-bio-reports-third-quarter-2025-financial-results-and-provides-corporate-update] (QTTB [https://seekingalpha.com/symbol/QTTB]): Q3 GAAP EPS of -$0.60 beats by $0.59. * Cash a…
Healthcare Rally: Pulmonx, UHS, And X4 Lead After-Hours Gains Amid Strategic Updates
(RTTNews) - Several healthcare and biotech stocks posted notable gains in after-hours trading on Monday, driven by earnings updates, executive appointments, and capital market activity. Pulmonx Corp. (LUNG) surged 33.33% to $2.08 as of 9:3…
Q32 Bio August 2025 slides: Bempikibart shows durable response in alopecia areata
Introduction & Market Context Q32 Bio Inc (NASDAQ:QTTB) presented its corporate overview in August 2025, highlighting the company’s focus on immune therapeutics with a primary emphasis on its lead candidate Bempikibart for alopecia areata…
Q32 Bio names interim chief medical officer
* Clinical-stage biotechnology company Q32 Bio (NASDAQ:QTTB [https://seekingalpha.com/symbol/QTTB]) appointed [https://seekingalpha.com/pr/20147073-q32-bio-appoints-adrien-sipos-m-d-ph-d-as-interim-chief-medical-officer] Adrien Sipos, M.D.…
Oxford Biomedica completes acquisition of remaining stake in U.S. subsidiary
OXB has acquired the remaining 10% stake in its US subsidiary from Q32 Bio (QTTB), bringing its ownership, as planned, to 100%. As previously disclosed in the Company’s Preliminary Results on 9 April, OXB US exercised its call option on 1…